全文获取类型
收费全文 | 527篇 |
免费 | 54篇 |
国内免费 | 27篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 7篇 |
基础医学 | 8篇 |
临床医学 | 18篇 |
内科学 | 51篇 |
神经病学 | 1篇 |
特种医学 | 3篇 |
外国民族医学 | 1篇 |
外科学 | 20篇 |
综合类 | 47篇 |
预防医学 | 11篇 |
药学 | 129篇 |
1篇 | |
中国医学 | 5篇 |
肿瘤学 | 304篇 |
出版年
2023年 | 5篇 |
2022年 | 1篇 |
2021年 | 9篇 |
2020年 | 15篇 |
2019年 | 8篇 |
2018年 | 14篇 |
2017年 | 21篇 |
2016年 | 20篇 |
2015年 | 24篇 |
2014年 | 40篇 |
2013年 | 38篇 |
2012年 | 48篇 |
2011年 | 54篇 |
2010年 | 38篇 |
2009年 | 65篇 |
2008年 | 62篇 |
2007年 | 37篇 |
2006年 | 27篇 |
2005年 | 22篇 |
2004年 | 14篇 |
2003年 | 12篇 |
2002年 | 4篇 |
2001年 | 3篇 |
2000年 | 5篇 |
1999年 | 5篇 |
1998年 | 9篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1995年 | 4篇 |
排序方式: 共有608条查询结果,搜索用时 31 毫秒
101.
Stathopoulos GP Tsavdaridis D Malamos NA Rigatos SK Kosmas Ch Pergantas N Stathopoulos JG Xynotroulas J 《Cancer chemotherapy and pharmacology》2005,56(5):487-491
Purpose: This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been established as agents for breast and colorectal cancer, respectively. Methods: Forty-eight (median age 54 years, range 26–77 year) patients, all evaluable, were enrolled. All patients had been pre-treated with anthracycline-combined chemotherapy, 30 of whom were also treated with paclitaxel and 2 with docetaxel. World Health Organization (WHO) performance status was 0–2. The dominant metastasis was in the liver (54.17%), in the lungs (27.08%), in soft tissues (12.50%) and in the skeleton (6.25%). Treatment involved irinotecan infusion 200 mg/m2 for 90 min and docetaxel infusion 80 mg/m2 for 90 min, repeated once every 3 weeks. Results: Twenty-five (52.08%, 95% confidence interval [CI] 37.95–66.21) patients showed responses: 3 complete (6.25%, 95% CI 0–13.05) and 22 (45.83%, 95% CI 31.74–59.92) partial; the most responsive metastases were observed at the liver site (53.85%). Grade 3 and 4 neutropenia was observed in 18 patients (37.50%); 14 (29.17%) patients developed anaemia and three (6.25%), thrombocytopenia. Concerning non-haematologic toxicity, alopecia and fatigue were common; grade 3 diarrhea was observed in only one (2.08%) patient. Conclusion: The irinotecan-docetaxel combination produces quite a high response rate in pre-treated advanced breast cancer patients. 相似文献
102.
V Alonso P Escudero M Zorrilla M.D Isla A Herrero J.I Mayordomo J Martinez-Trufero A Senz A Tres A Antn 《European journal of cancer (Oxford, England : 1990)》2001,37(18):475
The aim of this study was to determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly Irinotecan (CPT-11) plus UFT, and to assess the antitumour activity of this combination as second-line chemotherapy in patients with advanced colorectal carcinoma, 31 patients with measurable advanced colorectal carcinoma were treated. Cohorts of 3 patients received increasing dose levels of the combination. Levels 1 to 4 included a fixed dose of oral (p.o.) UFT (250 mg/m2/day) for 21 days of a 28-day cycle combined with increasing intravenous (i.v.) doses of CPT-11 (80, 100, 110 and 120 mg/m2) on days 1, 8 and 15. Levels 5 and 6 included a higher fixed dose of oral UFT (300 mg/m2) combined with increasing i.v. doses of CPT-11 (100 and 110 mg/m2) on days 1, 8 and 15. 147 courses were administered. MTD were reached at level 4 (2 cases of grade 4 diarrhoea and 1 grade 3 asthenia), and level 6 (1 grade 4 diarrhoea, 1 grade 3 diarrhoea and 1 grade 3 febrile neutropenia). Responses in 30 evaluable patients were: 3 partial responses (10%), 15 stable disease (50%) and progressive disease in 12 patients (40%). Median time to progression was 4.5 months (95% Confidence Interval (CI): 3.4–6.6 months) and median survival was 11 months (95% CI: 7.9–14.1 months). The recommended doses for phase II trials are: (a) CPT-11 110 mg/m2 i.v. on days 1, 8 and 15 every 28 days plus UFT 250 mg/m2 p.o. on days 1 through to 21 or (b) CPT-11 100 mg/m2 and UFT 300 mg/m2. 相似文献
103.
H. Sakai M. Diener V. Gartmann N. Takeguchi 《Naunyn-Schmiedeberg's archives of pharmacology》1995,351(3):309-314
Irinotecan (CPT-11) is active against a broad range of human cancer. One of the side-effects of irinotecan is a strong diarrhoea. In order to investigate the mechanism underlying this diarrhoea, the effect of irinotecan on anion secretion across the isolated rat distal colon was studied. Irinotecan caused a concentration-dependent increase in short-circuit current (Isc). The increase in Isc was completely dependent on the presence of Cl– ions and was supressed by furosemide and the Cl– channel blocker NPPB (5-nitro-2-(3-phenylpropylamino)-benzoate), indicating that it is caused by a Cl– secretion. The secretory response was inhibited by indomethacin, 1-benzylimidazole, a thromboxane synthase inhibitor, and SK&F 88046 ((N,Nbis-[7-(3-Chlorobenzeneaminosulfonyl)-1,2,3,4-tetrahydroisoquinolyl)disulfonylimide), a thromboxane A2 receptor blocker. In isolated crypts irinotecan had no effect on the membrane potential. Consequently, the secretion induced by irinotecan is an indirect one, caused by the stimulation of eicosanoid production, e.g. thromboxane A2, in the subepithelial tissue. 相似文献
104.
Sang Joon Shin Ki Chang Keum Jun Seok Im Seung Hyuk Baik Hei-Cheul Jeung Jae Kyung Roh Joong Bae Ahn 《Radiotherapy and oncology》2010,95(3):303-676
Background and purpose
The aim of this study is to evaluate the efficacy and safety of preoperative radiation therapy combined with S-1 and irinotecan (SI) in LARC.Materials and methods
Patients were considered LARC if they had a T3/T4 lesion or node positive. Weekly doses of 40 mg/m2 irinotecan were intravenously administered once per week during weeks 1-5 of radiotherapy. S-1 (70 mg/m2) was given from Monday to Friday in all weeks of radiotherapy. 3-D conformal radiotherapy was given at daily fractions of 1.8 Gy for 5 days for a total dose of 50.4 (45 + 5.4) Gy. Surgery was performed 4-6 weeks following the completion of chemoradiation.Results
Between June 2006 and November 2007, 43 pts were enrolled. The stage was: cT3 24 patients, cT4 6 patients; 28 patients were cN+. Forty-one patients completed the chemoradiation and 42 patients underwent operation: a low anterior resection was performed in 36 patients, a total colectomy in 1 patient, and an abdominal perineal resection in 5 patients. T downstaging was observed in 50%; 23 N+ patients became N− (55%). The complete pathological response was observed in 9 patients (21%). The 3-year locoregional failure rate, distant failure rate, disease-free survival, and overall survival were 9.5%, 18.6%, 72.1%, and 94.3%, respectively. Only three patients experienced G3 diarrhea; one had G3 sepsis and two had septic shock. Hematological toxicity (G3-G4) was observed in five patients.Conclusions
This study demonstrated the efficacy of preoperative CRT with S-1 and irinotecan with 21% of complete response. However, prompt recognition and management of infection is needed to use it in patients with locally advanced rectal cancer. 相似文献105.
Y. Ishii H. Hasegawa T. Endo K. Okabayashi H. Ochiai K. Moritani M. Watanabe Y. Kitagawa 《European journal of surgical oncology》2010
Aims
The aim of this study was to evaluate the usefulness of neoadjuvant systemic chemotherapy using irinotecan, 5-FU, and leucovorin (LV) for the treatment of locally advanced rectal cancer, which was a powerful ploychemotherapy in those days in Japan.Methods
Between 2001 and 2004, 26 patients with T3 or T4 and N0-2 non-metastatic resectable rectal cancer were selectively enrolled in this study. Neoadjuvant chemotherapy consisted of two cycles of irinotecan (80 mg/m2), 5-FU (500 mg/m2), and LV (250 mg/m2) on days 1, 8, and 15 for 4 weeks. Surgical resection was performed in all the patients 2–4 weeks after the completion of chemotherapy.Results
Overall down-staging was observed in 15 patients. T level and N level down-staging were observed in 12 and 13 patients, respectively. A pathological complete response was observed in one patients. The median follow-up period was 75 months (range, 8–97 months). Recurrences occurred in 5 patients including pelvic relapses in 3 and distant metastases in 2. The 5-year relapse-free and overall survival rates were 74% and 84%, respectively.Conclusions
Neoadjuvant systemic chemotherapy comprised of a combination of multi-drugs as irinotecan, 5-FU, and LV may be beneficial to the prognoses of patients with locally advanced rectal cancer. 相似文献106.
Masi G Cupini S Marcucci L Cerri E Loupakis F Allegrini G Brunetti IM Pfanner E Viti M Goletti O Filipponi F Falcone A 《Annals of surgical oncology》2006,13(1):58-65
Background The prognosis of unresectable metastatic colorectal cancer might be improved if a radical surgical resection of metastases
could be performed after a response to chemotherapy.
Methods We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan,
oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI). Because of the high activity of these regimens
(response rate, 72%), a secondary curative operation could be performed in 19 patients (26%).
Results Four patients underwent an extended hepatectomy, nine patients underwent a right hepatectomy, three patients underwent a left
hepatectomy, and three patients had a segmental resection. In five patients, surgical removal of extrahepatic disease was
also performed. In seven patients, surgical resection was combined with intraoperative radiofrequency ablation. The median
overall survival of the 19 patients who underwent operation is 36.8 months, and the 4-year survival rate is 37%. The median
overall survival of the 34 patients who were responsive to chemotherapy, but who did not undergo operation, is 22.2 months
(P = .0114).
Conclusions The FOLFOXIRI regimens we studied have significant antitumor activity and allow a radical surgical resection of metastases
in patients with initially unresectable metastatic colorectal cancer not selected for a neoadjuvant approach and also those
with extrahepatic disease. The median survival of patients with resected disease is promising. 相似文献
107.
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer 总被引:3,自引:0,他引:3
Hofheinz RD Horisberger K Woernle C Wenz F Kraus-Tiefenbacher U Kähler G Dinter D Grobholz R Heeger S Post S Hochhaus A Willeke F 《International journal of radiation oncology, biology, physics》2006,66(5):1384-1390
PURPOSE: To establish the feasibility and efficacy of chemotherapy with capecitabine, weekly irinotecan, cetuximab, and pelvic radiotherapy for patients with locally advanced rectal cancer. METHODS AND MATERIALS: Twenty patients with rectal cancer (clinical Stage uT3-T4 or N+) received a standard dosing regimen of cetuximab (400 mg/m(2) on Day 1 and 250 mg/m(2) on Days 8, 15, 22, and 29) and escalating doses of irinotecan and capecitabine according to phase I methods: dose level I, irinotecan 40 mg/m(2) on Days 1, 8, 15, 22, and 29 and capecitabine 800 mg/m(2) on Days 1-38; dose level II, irinotecan 40 mg/m(2) and capecitabine 1000 mg/m(2); and dose level III, irinotecan 50 mg/m(2) and capecitabine 1000 mg/m(2). Radiotherapy was given to a dose of 50.4 Gy (45 Gy plus 5.4 Gy). Resection was scheduled 4-5 weeks after termination of chemoradiotherapy. RESULTS: On dose level I, no dose-limiting toxicities occurred; however, Grade 3 diarrhea affected 1 of 6 patients on dose level II. Of 5 patients treated at dose level III, 2 exhibited dose-limiting toxicity (diarrhea in 2 and nausea/vomiting in 1). Therefore, dose level II was determined as the recommended dose for future studies. A total of 10 patients were treated on dose level II and received a mean relative dose intensity of 100% of cetuximab, 94% of irinotecan, and 95% of capecitabine. All patients underwent surgery. Five patients had a pathologically complete remission and six had microfoci of residual tumor only. CONCLUSION: Preoperative chemoradiotherapy with cetuximab, capecitabine, and weekly irinotecan is feasible and well tolerated. The preliminary efficacy is very promising. Larger phase II trials are ongoing. 相似文献
108.
A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer 总被引:3,自引:0,他引:3
Farhat FS 《Medical oncology (Northwood, London, England)》2007,24(2):137-146
Background The prognosis of gastric tumor is generally poor because most tumors are diagnosed at an advanced stage. Chemotherapy has
a proven palliative role in advanced gastric cancer and several combination regimens were explored in the last 10 yr. Nevertheless,
none of them showed a convincing improvement resulting in an enhancement of response rate and overall survival without discrimination
of the quality of life. Irinotecan (CPT11) has been evaluated in multiple trials alone or in combined therapy with promising
results and good tolerance. Thus, a review of the importance and impact of CPT11 in this indication is detailed.
Methods This article reviews the evidence for the use of CPT11 in the treatment of gastric cancer based on a computerized MEDLINE
search of literature published until August 2006 leading to a total of 91 publications.
Results CPT11 was frequently used and showed a good response rate varying from 14% to 23% as single agent and 45% to 70% in combination
with a median time to progression of 3 mo in single agent and 4–6 mo in combination, and median overall survival of approx
7 mo in single agent and up to 10.58 mo in combination.
Conclusion The overall response of irinotecan-based chemotherapy in advanced gastric cancer was shown to be as effective as other combined
chemotherapy. The hematological and digestive toxicity were tolerable and mild, especially in weekly regimen. Thus, irinotecan-based
chemotherapy should be considered as one of the preferred choices in front line chemotherapy in advanced gastric cancer. 相似文献
109.
Baetz T Eisenhauer E Siu L MacLean M Doppler K Walsh W Fisher B Khan AZ de Alwis DP Weitzman A Brail LH Moore M 《Investigational new drugs》2007,25(3):217-225
Summary
Background: LY293111 is an oral agent known to be a leukotriene B4 (LTB4) receptor antagonist and a 5-lipoxygenase inhibitor resulting
in selective inhibition of the lipoxygenase pathway. Lipoxygenases metabolize arachidonic acid and have been involved in cancer
cell proliferation and survival. In addition, LY293111 has been found to be a peroxisome proliferator activated receptor-gamma
(PPAR-γ) agonist. Antineoplastic activity of LY293111 has been identified in preclinical models both alone and in combination
with chemotherapy agents including irinotecan. The NCIC Clinical Trials Group studied LY293111 in combination with irinotecan
to determine the recommended dose of the combination and to describe its tolerability and pharmacokinetic interaction. In
addition the anti-tumour activity of LY293111 in combination with irinotecan was documented.
Patients and methods: Twenty-eight patients with advanced solid tumours were treated on seven dose levels with the combination of irinotecan and
LY293111. Irinotecan was administered intravenously every 21-days as a single dose. LY293111 was administered twice daily
continuously by mouth.
Results: Dose limiting toxicity (DLT) of grade 3 diarrhea was seen in two patients with doses of irinotecan 300 mg/m2 IV every 21-days in combination with LY293111 300 mg BID. Subsequently the dose of irinotecan was decreased to 250 mg/m2 IV every 21-days with escalating doses of LY293111. A DLT of grade 3 abdominal pain was seen at dose 600 mg BID of LY293111
with irinotecan 250 mg/m2. The pharmacokinetics (PK) indicated that the administration of LY293111 did not have an effect on the PK of irinotecan or
its metabolite SN-38. No responses were seen; seven patients had stable disease of a median duration of 4.4 months (range
2.8–13 months).
Conclusion: The recommended phase II dose of LY293111 is 600 mg orally BID in combination with irinotecan 250 mg/m2 IV every 21-days. Gastrointestinal adverse effects were common but could be well managed. 相似文献
110.
Colorectal cancer (CRC) is the fourth most common cancer in men and the third in women worldwide. Combinations of 5-fluorouracil (5-FU)/folinic acid (FA) with irinotecan or oxaliplatin form the standard treatment approaches for metastatic disease. The introduction of targeted agents has presented the opportunity to improve on the efficacy of current treatments without exacerbating the associated toxicity. Cetuximab (Erbitux®) is an IgG1 monoclonal antibody (MAb) that specifically targets the epidermal growth factor receptor (EGFR) with high affinity and competitively inhibits endogenous ligand binding. Cetuximab has shown good efficacy in combination with irinotecan in CRC that had previously progressed on irinotecan-based therapy. Cetuximab plus irinotecan and various schedules of 5-FU/FA have shown efficacy in a first-line setting. The activity of cetuximab and oxaliplatin-based regimens is being investigated in both first- and subsequent-line settings. Cetuximab is well tolerated and does not increase the side effect profile of agents it is combined with. Other EGFR inhibitors, including the tyrosine kinase inhibitors, gefitinib and erlotinib, and the MAbs, panitumumab and matuzumab, are also being investigated in a number of solid tumors. The vascular endothelial growth factor (VEGF) inhibitor, bevacizumab, although apparently inactive as a single agent, has demonstrated survival benefits when combined with bolus 5-FU/FA and irinotecan in a first-line setting and with 5-FU/FA and oxaliplatin in the second-line treatment of metastatic CRC. In this paper we discuss the use of targeted therapies in the treatment of metastatic CRC, with a focus on cetuximab. 相似文献